Cancer Care During the COVID-19 Pandemic: A Retrospective Study From a Najran Oncology Center.

Autor:	Badheeb AM; Oncology, King Khalid Hospital - Oncology Center, Najran, SAU.; Oncology, Hadhramout University, Mukalla, YEM., Musallam SH; Internal Medicine, King Khalid Hospital, Najran, SAU., Alyami AY; Internal Medicine, Najran University, Najran, SAU., Almakrami AH; Endocrinology, King Khalid Hospital, Najran, SAU., Al-Swedan AD; Infectious Disease, King Khalid Hospital, Najran, SAU., Ahmed F; Urology, Ibb University, Ibb, YEM., Badheeb M; Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, USA., Aedh AI; Internal Medicine, King Khalid Hospital, Najran, SAU., Obied HY; Surgery, Najran University, Najran, SAU.; Cardiac Surgery, King Khalid Hospital, Najran, SAU., Seada IA; Cardiothoracic Surgery, King Khalid Hospital, Najran, SAU., Alyami NH; Laboratory Medicine, Hematology Unit, Najran General Hospital, Najran, SAU., Elhadi M; Medicine, King Khalid Hospital, Najran, SAU., Aman AA; Internal Medicine, King Khalid Hospital, Najran, SAU., Alkarak S; General Surgery, King Khalid Hospital, Najran, SAU., Haridi HK; Academic Affairs, King Khalid Hospital, Najran, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jun 26; Vol. 16 (6), pp. e63252. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
DOI:	10.7759/cureus.63252
Abstrakt:	Background The COVID-19 pandemic significantly impacted healthcare systems globally, with cancer patients representing a particularly vulnerable group. This study aims to evaluate the influence of COVID-19 on cancer, focusing on infection rates, types of care, therapy adjustments, and factors associated with COVID-19 infection. Materials and methods This single-center retrospective analysis included adult cancer patients who underwent anticancer therapy at King Khalid Hospital in Najran, Saudi Arabia, from December 20, 2020, to January 23, 2022. Data on patient and cancer characteristics, COVID-19 specifics, treatment delays, outcomes, and factors associated with COVID-19 were collected and analyzed. Results A total of 257 chemotherapy recipients were interviewed. The mean age was 52.6 ± 14.4 years, with 44 (17.1%) over 65 years old. Females comprised 160 (62.3%) of the patients. The most common malignancies were gastrointestinal (71, 27.6%), breast (70, 27.2%), and hematological (50, 19.5%). Metastasis was present in 116 patients (45.1%). Common comorbidities included diabetes (68, 26.5%) and hypertension (55, 21.4%). Most patients (226, 87.9%) were vaccinated against COVID-19. COVID-19 tested positive in 22 patients (8.6%), with a lower infection rate in vaccinated patients (7 vs. 15, p < 0.001). Most cases were mild (18, 81.8%), with fever (19, 7.4%) and cough and fatigue (17, 6.6%) being the most common symptoms. The median time to resume treatment post-infection was 30 days. Factors associated with higher infection rates included diabetes (OR: 4.73, 95% CI: 1.94-12.03, p = 0.001), coronary artery disease (OR: 4.13, 95% CI: 1.07-13.30, p = 0.049), chronic lung disease (OR: 15.58, 95% CI: 5.37-45.79, p < 0.001), chronic liver disease (OR: 7.64, 95% CI: 2.38-22.98, p < 0.001), and multiple comorbidities (OR: 2.04, 95% CI: 1.46-2.90, p < 0.001), cancer patients who received chemotherapy (OR: 1.02, 95% CI: 0.12-12.79, p = 0.027), and immunotherapy (OR: 3.37, 95% CI:1.27-8.43, p = 0.012). Conclusion The incidence of COVID-19 in cancer patients is proportional to the prevalence in the general population of similar geographic areas. Diabetes, coronary artery disease, chronic lung disease, chronic liver disease, receiving chemotherapy or immunotherapy, and multiple comorbidities were associated with higher COVID-19 infection rates. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Ethics Research Committees, King Khalid Hospital issued approval KACST, KSA: H-I1-N-089. The study was approved by the Ethics Research Committees of King Khalid Hospital in compliance with the ethical standards outlined in the Declaration of Helsinki. Due to the anonymous retrospective nature of the study, written informed consent from the included patients was not required. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Badheeb et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu